Citations

Clear

3942 citation(s) found for "To, Van".

Underreporting and Underrepresentation of Race and Ethnicity in Head and Neck Cancer Trials, 2010-2020
Sauer, Adam , Daher, Ghazal S. , Lohse, Christine M. , Glasgow, Amy E. , Douse, Dontre’ M. , Moore, Eric J. , Ighodaro, Eseosa T. , Abel, Kathryn M. Van , Glasgow, Amy E. , Sauer, Adam B, Van Abel, Kathryn M , Glasgow, Amy E , Habermann, Elizabeth B. , Yin, Linda X.

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | June 2, 2022 | Volume: 148 | Issue: 7 | Pages: 662

10.1001/jamaoto.2022.1028 | PMID 35653143 Get It

Introduction. Best practices in telemedicine for optimizing patient care
Stroink, Ann R., Servadei, Franco , Drummond, Katharine Jann , Gompel, Jamie J. Van

Mayo Clinic

Neurosurgical Focus | June 1, 2022 | Volume: 52 | Issue: 6 | Pages: E1

10.3171/2022.3.focus22149 | PMID 35921189 Get It

Retrospective Review of Surgical Site Infections after Endoscopic Endonasal Sellar and Parasellar Surgery: Multicenter Quality Data from the North American Skull Base Society
Saleh, Sara , Sullivan, Stephen E., Roxbury, Christopher R. , Das, Paramita , Hachem, Ralph Abi , Ackall, Feras , Jang, David W. , Çeltikçi, Emrah , Şahin, Muammer Melih , D’Souza, Glen , Evans, James J., Nyquist, Gurston , Khalafallah, Adham M. , Mukherjee, Debraj , Camp, Samantha, Ghiam, Michael K. , Levine, Corinna G. , Field, Melvin , Adappa, Nithin D. , Rassekh, Christopher H. , Sweis, Auddie M. , Wilson, Meghan, Patel, Shivam , Gardner, Paul A. , Glancz, Laurence , Bagchi, Ananyo , Dow, Graham, Robertson, Iain, Rangarajan, Sanjeet V., Celtikci, Emrah , Mukherjee, Debraj , Rowan, Nicholas R , Van Gompel, Jamie J , Goyal, Neerav , Saleh, Sara , Bellile, Emily Light , Rowan, Nicholas R. , Camp, Samantha , Choby, Garret , Gompel, Jamie J. Van , Adappa, Nithin D. , Locke, Tran B. , Zacharia, Brad E. , Snyderman, Carl H , Wang, Eric W , Michael, Lattimore Madison , McKean, Erin L.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | June 1, 2022 | Volume: 83 | Issue: 06 | Pages: 579-588

10.1055/a-1865-3202 | PMID 36393885 Get It

Abstract Introduction Transnasal access to the anterior skull base provides a minimally invasive approach for sellar and parasellar masses compared with its open counterparts. The unique microbiome of the sinonasal mucosa provides distinct challenges not encountered with other cranial approaches. The use of antibiotics in these cases has not been standardized, and data remain scarce regarding infectious outcomes. Methods We conducted a multicenter retrospective analysis of shared quality data points for the endoscopic endonasal approach (EEA) for pituitary adenomas, along with other sellar and parasellar region masses that were included by participating institutions. Patient and operative characteristics, perioperative and postoperative antibiotic regimens and their durations, intraoperative and postoperative cerebrospinal fluid leak, and onset of postoperative meningitis and sinusitis were compared. Results Fifteen institutions participated and provided 6 consecutive months' worth of case data. Five hundred ninety-three cases were included in the study, of which 564 were pituitary adenomectomies. The incidences of postoperative meningitis and sinusitis were low (0.67 and 2.87% for all pathologies, respectively; 0.35% meningitis for pituitary adenomas) and did not correlate with any specific antibiotic regimen. Immunocompromised status posed an increased odds of meningitis in pituitary adenomectomies (28.6, 95% confidence interval [1.72–474.4]). Conclusions The results show no clear benefit to postoperative antimicrobial use in EEA, with further larger studies needed.
Calibration and standardization of extracellular vesicle measurements by flow cytometry for translational prostate cancer research
Arafa, Ali , Thapa, Ishwor , Britton, Cameron J. , Kosti, Jorgena, Song, Siyang , Joshi, Vidhu B. , Erickson, Ree M., J Britton, Cameron, Joshi, Vidhu B , M Erickson, Ree, Lucien, Fabrice , Kim, Yohan , van der Pol, Edwin , Ali, Hesham , Lucien, Fabrice

Mayo Clinic

Nanoscale | May 31, 2022 | Volume: 14 | Issue: 27 | Pages: 9781-9795

10.1039/d2nr01160c | PMID 35770741 Get It

Higher levels of tumor-derived extracellular vesicles are detected in metastatic prostate cancer compared to localized prostate cancer by standardized and calibrated flow cytometry.
Typical, atypical and cryptic t(15;17)(q24;q21) ( PML::RARA ) observed in acute promyelocytic leukemia: A retrospective review of 831 patients with concurrent chromosome and PML::RARA
Gagnon, Marie‐France, Berg, Holly , Meyer, Reid G., Sukov, William R. , Dyke, Daniel L. Van , Jenkins, Robert B. , Greipp, Patricia T. , Thorland, Erik C., Hoppman, Nicole L., Xu, Xinjie , Reichard, Kaaren K. , Peterson, Jess F. , Berg, Holly E, Van Dyke, Daniel L, Baughn, Linda B , Peterson, Jess F , Greipp, Patricia T , Gagnon, Marie-France, Baughn, Linda B. , Ketterling, Rhett P.

Mayo Clinic

Genes, Chromosomes and Cancer | May 31, 2022 | Volume: 61 | Issue: 10 | Pages: 629-634

10.1002/gcc.23070 | PMID 35639830 Get It

Abstract The diagnosis of acute promyelocytic leukemia (APL) relies on the identification of PML::RARA fusion. While the majority of APL cases harbor a typical t(15;17)(q24;q21), atypical genetic mechanisms leading to the oncogenic PML::RARA fusion have been reported yet their frequency and scope remain poorly characterized. We assessed the genetic findings of 831 cases with APL investigated with concurrent chromosome banding analysis and dual‐color dual‐fusion fluorescence in situ hybridization (D‐FISH) analysis at our institution over an 18.5‐year timeframe. Seven hundred twenty‐three (87%) cases had a typical balanced t(15;17) with both testing modalities. Atypical karyotypic results including complex translocations, unbalanced rearrangements and insertional events occurred in 50 (6%) cases, while 6 (0.7%) cases were cryptic by conventional chromosome studies despite PML::RARA fusion by D‐FISH evaluation. Atypical FISH patterns were observed in 48 (6%) cases despite apparently balanced t(15;17) on chromosome banding analysis. Two hundred fifty (30%) cases displayed additional chromosome abnormalities of which trisomy/tetrasomy 8 (37%), del(7q)/add(7q) (12%), and del(9q) (7%) were most frequent. Complex and very complex karyotypes were observed in 81 (10%) and 34 (4%) cases, respectively. In addition, 4 (0.5%) cases presented as an apparently doubled, near‐tetraploid stemline clone. This report provides the largest appraisal of cytogenetic findings in APL with conventional chromosome and PML::RARA D‐FISH analysis. By characterizing the frequency and breadth of typical and atypical results through the lens of these cytogenetic testing modalities, this study serves as a pragmatic source of information for those involved in the investigation of APL in both the clinical and research laboratory settings.
Utilization of Antitumor Necrosis Factor Biologics in Very Early Onset Inflammatory Bowel Disease
Kerur, Basavaraj , Fiedler, Karoline , Stahl, Marisa G. , Hyams, Jeffrey S. , Stephens, Michael C., Lu, Ying , Pfefferkorn, Marian, Alkhouri, Raza, Strople, Jennifer , Kelsen, Judith R. , Siebold, Leah, Goyal, Alka , Rosh, Joel R. , LeLeiko, Neal S. , Limbergen, Johan Van , Maltz, Ross , Karam, Lina , Heyman, Melvin B. , Benkov, Keith , Noe, Joshua D. , Moulton, Dedrick E., Pappa, Helen, Galanko, Joseph A. , Muise, Aleixo M. , Stephens, Michael, Leleiko, Neal S , Guerrerio, Anthony L. , Crowley, Eileen , Griffiths, Anne Marie , Deneau, Mark , Snapper, Scott B. , Kappelman, Michael D. , Benchimol, Eric I.

Mayo Clinic

Journal of Pediatric Gastroenterology and Nutrition | May 27, 2022 | Volume: 75 | Issue: 1 | Pages: 64-69

10.1097/mpg.0000000000003464 | PMID 35622080 Get It

Background:Research on the utilization and effectiveness of antitumor necrosis factor (TNF) biologics in children with very early onset inflammatory bowel disease (VEOIBD) is urgently needed. Here we describe anti‐TNF use and durability in a multicenter cohort.Methods:We performed a retrospective cohort study of patients diagnosed with VEOIBD (<6 years) between 2008 and 2013 at 25 North American centers. We performed chart abstraction at diagnosis and 1, 3, and 5 years after diagnosis. We examined the rate of initiation and durability of infliximab and adalimumab and evaluated associations between treatment durability and the following covariates with multivariate Cox proportional hazard regression: age at diagnosis, sex, disease duration, disease classification, and presence of combined immunomodulatory treatment versus monotherapy.Results:Of 294 children with VEOIBD, 120 initiated treatment with anti‐TNF therapy and 101 had follow‐up data recorded [50% Crohn disease (CD), 31% ulcerative colitis (UC), and 19% IBD unclassified (IBD‐U)]. The cumulative probability of anti‐TNF treatment was 15% at 1 year, 30% at 3 years, and 45% at 5 years from diagnosis; 56 (55%) were treated between 0 and 6 years old. Anti‐TNF durability was 90% at 1 year, 75% at 3 years, and 55% at 5 years. The most common reason for discontinuation of anti‐TNF were loss of response in 24 (57%) children. Children with UC/IBD‐U had lower durability than those with CD (hazard ratio [HR] 0.17; 95% confidence interval [CI], 0.06–0.51; P = 0.001).Conclusions:Utilization and durability of anti‐TNF in VEOIBD is relatively high and comparable with older children. Having Crohn disease (compared with UC/IBD‐U) is associated with greater durability.
Generalizability of the EAST‐AFNET 4 Trial: Assessing Outcomes of Early Rhythm‐Control Therapy in Patients With Atrial Fibrillation
Dickow, Jannis , Kirchhof, Paulus , Houten, Holly K. Van , Sangaralingham, Lindsey R. , Dinshaw, Leon , Friedman, Paul A. , Packer, Douglas L. , Noseworthy, Peter A. , Yao, Xiaoxi , Van Houten, Holly K , Dinshaw, Leon H W , Noseworthy, Peter A , Kirchhof, Paulus , Yao, Xiaoxi

Mayo Clinic

Journal of the American Heart Association | May 27, 2022 | Volume: 11 | Issue: 11 | Pages: No page available

10.1161/jaha.121.024214 | PMID 35621202 Get It

Background EAST‐AFNET 4 (Early Treatment of Atrial Fibrillation for Stroke Prevention Trial) demonstrated clinical benefit of early rhythm‐control therapy (ERC) in patients with new‐onset atrial fibrillation (AF) and concomitant cardiovascular conditions compared with current guideline‐based practice. This study aimed to evaluate the generalizability of EAST‐AFNET 4 in routine practice. Methods and Results Using a US administrative database, we identified 109 739 patients with newly diagnosed AF during the enrollment period of EAST‐AFNET 4. Patients were classified as either receiving ERC, using AF ablation or antiarrhythmic drug therapy, within the first year after AF diagnosis (n=27 106) or not receiving ERC (control group, n=82 633). After propensity score overlap weighting, Cox proportional hazards regression was used to compare groups for the primary composite outcome of all‐cause mortality, stroke, or hospitalization with the diagnoses heart failure or myocardial infarction. Most patients (79 948 of 109 739; 72.9%) met the inclusion criteria for EAST‐AFNET 4. ERC was associated with a reduced risk for the primary composite outcome (hazard ratio [HR], 0.85; 95% CI, 0.75–0.97 [ P =0.02]) with largely consistent results between eligible (HR, 0.89; 95% CI, 0.76–1.04 [ P =0.14]) or ineligible (HR, 0.77; 95% CI, 0.60–0.98 [ P =0.04]) patients for EAST‐AFNET 4 trial inclusion. ERC was associated with lower risk of stroke in the overall cohort and in trial‐eligible patients. Conclusions This analysis replicates the clinical benefit of ERC seen in EAST‐AFNET 4. The results support adoption of ERC as part of the management of recently diagnosed AF in the United States.
Enthesis Healing Is Dependent on Scaffold Interphase Morphology—Results from a Rodent Patellar Model
Silva, Carlos Julio Peniche , Quirk, Nicholas , Poh, Patrina S. P. , Mayer, Carla, Migliaresi, Claudio , Coenen, Michael J., Evans, Christopher H. , Balmayor, Elizabeth R. , Griensven, Martijn van , Peniche Silva, Carlos J , Müller, Sebastian A. , Quirk, Nicholas , Migliaresi, Claudio , Balmayor, Elizabeth R , van Griensven, Martijn , Müller, Sebastian , Motta, Antonella

Mayo Clinic

Cells | May 26, 2022 | Volume: 11 | Issue: 11 | Pages: 1752

10.3390/cells11111752 | PMID 35681447 Get It

The use of multiphasic scaffolds to treat injured tendon-to-bone entheses has shown promising results in vitro. Here, we used two versions of a biphasic silk fibroin scaffold to treat an enthesis defect created in a rat patellar model in vivo. One version presented a mixed transition between the bony and the tendon end of the construct (S-MT) while this transition was abrupt in the second version (S-AT). At 12 weeks after surgery, the S-MT scaffold promoted better healing of the injured enthesis, with minimal undesired ossification of the insertion area. The expression of tenogenic and chondrogenic markers was sustained for longer in the S-MT-treated group and the tangent modulus of the S-MT-treated samples was similar to the native tissue at 12 weeks while that of the S-AT-treated enthesis was lower. Our study highlights the important role of the transition zone of multiphasic scaffolds in the treatment of complex interphase tissues such as the tendon-to-bone enthesis.
MDACT: A New Principle of Adjunctive Cancer Treatment Using Combinations of Multiple Repurposed Drugs, with an Example Regimen
Kast, Richard E. , Alfieri, Alex , Assi, Hazem , Elyamany, Ashraf , González‐Cao, María , Karpel‐Massler, Georg , Marosi, Christine , Salacz, Michael, Sardi, Iacopo , Vlierberghe, Pieter Van , Zaghloul, Mohamed S. , Halatsch, Marc‐Eric , Assi, Hazem I , Elyamany, Ashraf M , Gonzalez-Cao, Maria , Sardi, Iacopo , Van Vlierberghe, Pieter , Zaghloul, Mohamed S , Halatsch, Marc-Eric , Burns, Terry C.

Mayo Clinic

Cancers | May 23, 2022 | Volume: 14 | Issue: 10 | Pages: 2563

10.3390/cancers14102563 | PMID 35626167 Get It

In part one of this two-part paper, we present eight principles that we believe must be considered for more effective treatment of the currently incurable cancers. These are addressed by multidrug adjunctive cancer treatment (MDACT), which uses multiple repurposed non-oncology drugs, not primarily to kill malignant cells, but rather to reduce the malignant cells’ growth drives. Previous multidrug regimens have used MDACT principles, e.g., the CUSP9v3 glioblastoma treatment. MDACT is an amalgam of (1) the principle that to be effective in stopping a chain of events leading to an undesired outcome, one must break more than one link; (2) the principle of Palmer et al. of achieving fractional cancer cell killing via multiple drugs with independent mechanisms of action; (3) the principle of shaping versus decisive operations, both being required for successful cancer treatment; (4) an idea adapted from Chow et al., of using multiple cytotoxic medicines at low doses; (5) the idea behind CUSP9v3, using many non-oncology CNS-penetrant drugs from general medical practice, repurposed to block tumor survival paths; (6) the concept from chess that every move creates weaknesses and strengths; (7) the principle of mass—by adding force to a given effort, the chances of achieving the goal increase; and (8) the principle of blocking parallel signaling pathways. Part two gives an example MDACT regimen, gMDACT, which uses six repurposed drugs—celecoxib, dapsone, disulfiram, itraconazole, pyrimethamine, and telmisartan—to interfere with growth-driving elements common to cholangiocarcinoma, colon adenocarcinoma, glioblastoma, and non-small-cell lung cancer. gMDACT is another example of—not a replacement for—previous multidrug regimens already in clinical use, such as CUSP9v3. MDACT regimens are designed as adjuvants to be used with cytotoxic drugs.